| abstract |
The present invention relates to a method for treating motor abnormalities associated with the pathology of neurological movement disorders, such as Parkinson's disease or restless leg syndrome, by administering a therapeutically effective amount of a PDE7 inhibitor. One aspect of the invention provides methods of administering a PDE inhibitor in combination with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitor may be selective for PDE7 relative to other molecular targets that are (i) known to be involved in Parkinson's disease pathology, or (ii) therapeutically effective for the treatment of Parkinson's disease molecular targets of other drugs. |